Correction to: Translational Psychiatry https://doi.org/10.1038/s41398-024-02973-1, published online 10 June 2024
In Table 1 of this article, the column headed year was not wide enough to show the exact year.
Table 1 should appear like that:
Study | Year | Race | Method | Frequency | Primary intervention | Blind assessment | Type of patients | Type of treatment setting | Type of effect | Sample size | Age (years) Mean/median (range) | Male (%) | Trial duration | Diagnostic tools | Suicidal ideation remission definition | Ketamine dosage |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wei Zheng [43] | 2022 | Asian | Intravenous | Repeatedly | Ketamine | Single arm | MDD or BD | Inpatient | Long term duration | 60 | 35.3 (12.4) | 27 (45%) | 12 days | DSM-V | SSI part I <2 | 0.5 mg/kg |
Mocrane Abbar [44] | 2021 | European | Intravenous | Repeatedly | Ketamine/Placebo | Double-Blinded | Bipolar, Depressive | Inpatient | Acute | 73/83 | 38 (18-75)/41 (18-76) | 19 (26.0)/31 (37.3) | 6 weeks | DSM-IV | SSI score of 0 to 3 | 0.5 mg/kg |
Anna Feeney [45] | 2021 | American | Intravenous | Single | Ketamine/Midazolam | Double-Blinded | MDD | Outpatients | Long term duration | 40/16 | 45.75±12.32 | 28 (50%) | 3 days | DSMIV-TR TM | MADRS suicide item < 2 | 0.1 mg/kg, 0.5 mg/kg, 1.0 mg/kg |
Yoav Domany [46] | 2021 | American | Intranasal | Ringle | Ketamine/Placebo | Double-Blinded | Mental disorders | Inpatient | Acute | 15/15 | 35.11 (8.67)/35.78 (9.86) | 4 (44.4%) /4 (44.4%) | 4 hours | NR | MADRS suicide item = 0 | 40 mg |
Carla M. Canuso [47] | 2021 | American | Intranasal | Repeatedly | Esketamine/Placebo | Double-Blinded | MDD | Inpatient | Acute | 222/224 | 40.5 (12.92) /39.6 (13.08) | 92 (40.7) /85 (37.8) | 4 weeks | DSM-V | CGI-SS-r score of 0 to 1 | 84 mg |
Yanling Zhou [48] | 2020 | Asian | Intravenous | Repeatedly | Ketamine | Single arm | Depression | Inpatient | Long term duration | 73 | 35.2(11.8) | 35(47.9) | 12 days | DSM-V | SSI part I <2 | 0.5 mg/kg |
Carla M. Canuso [49] | 2018 | American | Intranasal | Repeatedly | Esketamine/Placebo | Double-Blinded | Major depression | Inpatient | Acute | 35/31 | 35.7 (13.40) /36.0 (12.82) | 13 (37.1) /10 (32.3) | 4 weeks | DSM-IV-TR | CGI-SS-r score of 0 to 1 | 84 mg |
Roger S McIntyre [7) | 2020 | American | Intravenous | Repeatedly | Ketamine | Single arm | MDD or BD | Outpatients | Long term duration | 213 | 45 (15) | 95 (44.6) | 2 weeks | DSM-V | QIDS-SR16 = 0 | 0.5 ~ 0.75 mg/kg |
Rebecca B. Price [50] | 2014 | American | Intravenous | Single | Ketamine/Midazolam | Double-Blinded | TRD | Outpatients | Acute | 36/21 | 48.6 (11.4)/43.8 (10.9) | 16 (44%)/11 (52%) | 24 hours | DSM-IV-TR | QIDS-SR16 = 0 | 0.5 mg/kg |
Dawn F. Ionescu [51) | 2019 | American | Intravenous | Repeatedly | Ketamine/Placebo | Double-Blinded | MDD | Outpatients | Long term duration | 13/13 | 45.5 (13.6) /45.3 (11.7) | 6 (46%) /10 (77%) | 3 weeks | DSM-IV | C-SSRS SI score = 0 | 0.5 mg/kg |
Yoav Domany [52) | 2019 | American | Intravenous | Single | Ketamine/Placebo | Double-Blinded | MDD, BD, Depression, Dysthymia | Inpatient | Acute | 9/9 | 35.11 (8.67)/35.78 (9.86) | 4 (44.4%)/4 (44.4%) | 24 hours | MINI | MADRS suicide item score of 0 to 2 | 0.2 mg/kg |
Michael F. Grunebaum [9] | 2018 | American | Intravenous | Single | Ketamine/Midazolam | Double-Blinded | MDD | Inpatient | Acute | 40/40 | 38.4 (13.2)/40.7 (13.1) | 18(45%)/14 (35%) | 24 hours | DSM-IV | SSI <3 | 0.5 mg/kg |
LT John Burger [53] | 2016 | American | Intravenous | Single | Ketamine/Placebo | Double-Blinded | Depression | Inpatient | Acute | 3/7 | 28/27 | 2 (67%)/5 (71%) | 4 hours | NR | SSI score of 0 to 3 | 0.2 mg/kg |
Zhan Yanni [54] | 2019 | Asian | Intravenous | Repeatedly | Ketamine | Single arm | Depression | Inpatient | Long term duration | 86 | 33.99 (11.65) | 43 (50.0%) | 12 days | DSM-V (SCID-5) | SSI part I <2 | 0.5 mg/kg |
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Shen, Z., Gao, D., Lv, X. et al. Correction: A meta-analysis of the effects of ketamine on suicidal ideation in depression patients. Transl Psychiatry 14, 302 (2024). https://doi.org/10.1038/s41398-024-02979-9
Published:
Version of record:
DOI: https://doi.org/10.1038/s41398-024-02979-9
